NCT00523042 (iINHALE 9) is a Phase 3 clinical trial of insulin aspart in Diabetes, sponsored by Novo Nordisk A/S.

Who is sponsoring NCT00523042?

NCT00523042 is sponsored by Novo Nordisk A/S.

What drugs are being tested in NCT00523042?

Interventions in NCT00523042: insulin aspart, inhaled human insulin.

What condition does NCT00523042 study?

NCT00523042 studies Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Asthma.

Is NCT00523042 still recruiting?

NCT00523042 is currently terminated. Last updated 5 September 2018.

Last reviewed 2018-09-05 · How we verify

NCT00523042: iINHALE 9

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety of Inhaled Preprandial Human Insulin in Subjects With Diabetes and Asthma

Terminated Phase 3 Last updated 5 September 2018

What this trial tests

Phase 3 trial testing insulin aspart in Diabetes in 10 participants. Terminated before completion.

Timeline

30 August 2007

Primary endpoint
28 February 2008

28 February 2008

Quick facts

Lead sponsor	Novo Nordisk A/S
Phase	Phase 3
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	10
Start date	30 August 2007
Primary completion	28 February 2008
Estimated completion	28 February 2008
Sites	32 locations across Slovakia, Serbia and Montenegro, Malaysia, Australia, United States, India

Drugs / interventions tested

insulin aspart (INSULIN ASPART) — full drug profile →
inhaled human insulin — full drug profile →

Conditions studied

Diabetes — all drugs for Diabetes →
Diabetes Mellitus, Type 1 — all drugs for Diabetes Mellitus, Type 1 →
Diabetes Mellitus, Type 2 — all drugs for Diabetes Mellitus, Type 2 →
Asthma — all drugs for Asthma →

Sponsor

Novo Nordisk A/S — full company profile →

Who can join

18 and older, any sex, with Diabetes or Diabetes Mellitus, Type 1. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial is conducted in Europe, Asia, Oceania and the United States of America (USA). This is a one-year clinical trial to compare the safety of inhaled preprandial human insulin to subcutaneous insulin aspart in subjects with type 1 or 2 diabetes and asthma.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of insulin aspart

Trials testing the same drug.

NCT05946785 — Oxidative Stress in Microvascular Dysfunction Following Gestational Diabetes · EARLY_PHASE1 · recruiting
NCT05013229 — A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semagluti · Phase 3 · completed
NCT04848480 — A Research Study to Compare a New Weekly Insulin, Insulin Icodec, and an Available Daily Insulin, Insulin Degludec, Both · Phase 3 · completed
NCT02825251 — Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart Compared to NovoRapid® i · Phase 3 · completed
NCT02500706 — Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in · Phase 3 · completed

Other recruiting trials for Diabetes

Currently open trials in the same condition.

NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07479134 — Production of Stem Cells for the Generation of Pancreatic Cells · NA · recruiting
NCT07441655 — Families Implementing Good Health Traditions for Life · NA · recruiting
NCT06724172 — CHIME: Comparing Health Interventions for Maternal Equity · NA · recruiting
NCT07417865 — ECHO Diabetes FQHC · recruiting

Other Novo Nordisk A/S trials

Trials by the same sponsor.

NCT07357740 — A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes · Phase 2 · not yet recruiting
NCT07282613 — A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adoles · Phase 3 · not yet recruiting
NCT07357766 — A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight · Phase 3 · not yet recruiting
NCT07564414 — A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obe · Phase 3 · not yet recruiting
NCT07400107 — AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Exc · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00523042 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novo Nordisk A/S
Last refreshed: 5 September 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00523042.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing